ClinConnect ClinConnect Logo
Search / Trial NCT00921570

The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension

Launched by GULHANE SCHOOL OF MEDICINE · Jun 15, 2009

Trial Information

Current as of July 21, 2025

Completed

Keywords

Tweak Fmd Ptx3 Valsartan Amlodipine Renin Angiotensin System

ClinConnect Summary

The patients who were non-obese (BMI\<30kg/m2), non dyslipidemic (total cholesterol \<200mg/dl, Triglyceride\<150mg/dl), and free of cardiovascular events (negative medical history, negative ECG findings) were investigated for enrollment. CKD stage 1 patients older than 18 years of age and willing to participate to the study were screened. From the 375 patients with established type 2 diabetes mellitus+hypertension, 174 had proteinuria and/or hypertension (24 h protein excretion 1-2 g/day, systolic blood pressures ≥140mmHg and/or diastolic blood pressures ≥ 90 mmHg, respectively). All cases...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • CKD stage 1 patients
  • Older than 18 years of age
  • Type 2 Diabetic patients
  • Proteinuria
  • Hypertension
  • Exclusion Criteria:
  • History of coronary artery disease
  • Smokers
  • Taking statins or renin-angiotensin blockers

About Gulhane School Of Medicine

Gulhane School of Medicine is a prestigious medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to excellence in education and patient care, the school fosters a collaborative environment where multidisciplinary teams work to explore new treatment modalities and enhance medical knowledge. By engaging in rigorous clinical research, Gulhane School of Medicine aims to contribute to the development of effective therapies and improve health outcomes, ultimately benefitting both the local and global communities.

Locations

Ankara, , Turkey

Patients applied

0 patients applied

Trial Officials

Mahmut Ilker Yilmaz, MD

Principal Investigator

GATA

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials